腎臓がん治療の世界市場動向及び予測...市場調査レポートについてご紹介

【英文タイトル】Renal Cancer Treatment: Industry Analysis, R&D Trends and World Market Forecasts 2015-2025

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 Global Market Overview of the Renal Cancer Treatment Market
1.2 Benefits of This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analytical Report
1.5 Who is This Report For?
1.6 Methods of the Study
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain

2. An Introduction to Renal Cancer Treatments
2.1 What is Renal Cancer?
2.2 Renal Cancer Drug Treatments
2.3 Defining the Renal Cancer Treatment Market

3. Leading Renal Cancer Drugs and Leading Companies: Profiles and Forecasts from 2015-2025
3.1 Angiogenesis Inhibitors Lead the Market
3.1.1 Sutent (sunitinib) – Pfizer
3.1.2 Nexavar (sorafenib) – Bayer/Onyx
3.1.3 Votrient (pazopanib) – Novartis
3.1.4 Inlyta (axitinib) – Pfizer
3.2 mTOR Inhibitors Are Strong Competitors
3.2.1 Afinitor/Votubia (everolimus) – Novartis
3.2.2 Torisel (temsirolimus) – Pfizer
3.3 Monoclonal Antibodies: One Drug Makes a Difference
3.3.1 Avastin (bevacizumab) – Roche
3.4 Immunotherapies: A Market to Watch
3.4.1 Proleukin (aldesleukin) – Novartis/Prometheus Laboratories
3.5 Leading Companies in the Renal Drug Treatment Market
3.5.1 Pfizer: Current Market Leader
3.5.2 Novartis: Building Up Strengths
3.5.3 Roche: Expanding Blockbuster Avastin
3.5.4 Bayer Healthcare and Onyx Pharmaceuticals
3.5.5 Other Companies of Interest
3.5.5.1 Exelixis, Bristol-Myers Squibb, Merck and Cerulean Pharma

4. Anti-Cancer Renal Treatments: World Market Outlook and Forecast 2015-2025
4.1 The World Market for Renal Cancer Treatments in 2014
4.2 Leading Renal Cancer Drug Treatments in 2014
4.3 World Revenue Forecasts 2015-2025: Changing Market Shares for the Renal Cancer Treatment Market
4.4 Leading Anti-Cancer Renal Treatment Submarkets 2015-2025
4.4.1 Angiogenesis Inhibitors Lead the Current Market
4.4.2 Monoclonal Antibodies: Avastin is a Strong Competitor
4.4.3 An Important Submarket: mTOR Inhibitors
4.4.4 Summary: Angiogenesis Inhibitors and mTOR Inhibitors Lead the Market in 2015
4.5 Drivers and Restraints of the Renal Cancer Treatment Market 2015-2025
4.5.1 Drivers of the Renal Cancer Treatment Market
4.5.2 Restraints of the Renal Cancer Treatment Market

5. Leading National Markets for the Renal Cancer Treatment Market 2015-2025
5.1 Regional Breakdown of the World Renal Cancer Treatment Market 2014
5.2 World Renal Cancer Treatment Market: Regional Forecasts 2015-2025
5.2.1 How Will Regional Market Shares Change to 2025?
5.3 The US Renal Cancer Treatment Market 2015-2025
5.3.1 The US Renal Cancer Treatment Market: Drivers and Restraints
5.4 The EU Renal Cancer Treatment Market 2015-2025
5.4.1 The Renal Cancer Treatment Market in Germany to 2025
5.4.2 The Renal Cancer Treatment Market in France to 2025
5.4.3 The Renal Cancer Treatment Market in Italy to 2025
5.4.4 The Renal Cancer Treatment Market in the UK to 2025
5.4.5 The Renal Cancer Treatment Market in Spain to 2025
5.5 The Japanese Renal Cancer Treatment Market
5.6 The Renal Cancer Treatment Market in the Emerging Market: BRIC Market Forecast 2015-2025
5.6.1 The Renal Cancer Treatment Market in China to 2025
5.6.2 The Renal Cancer Treatment Market in Brazil to 2025
5.6.3 The Renal Cancer Treatment Market in Russia to 2025
5.6.4 The Renal Cancer Treatment Market in India to 2025

6. Renal Cancer Drugs Industry: R&D Pipeline Analysis
6.1 Targeted Therapies in Development for the Treatment of Renal Cancer
6.1.1 Lenvima (lenvatinib) – Eisai Inc
6.1.2 Cometriq (cabozantinib) – Exelixis
6.1.3 Dovitinib (TKI258) – Novartis
6.1.4 Linifanib (ABT-869) – Abbott Laboratories
6.1.5 Tivozanib – Aveo Pharmaceuticals
6.1.6 BEZ235 – Novartis
6.1.7 Tivantinib (ARQ197) – Daiichi Sankyo/ArQule
6.1.8 Cediranib (AZD2171/Recentin) – AstraZeneca
6.2 Immunotherapies in Development for the Treatment of Renal Cancer
6.2.1 Opdivo (nivolumab) – Bristol-Myers Squibb
6.2.2 AGS-003 – Argos Therapeutics
6.2.3 IMA901- Immatics Biotechnologies/Roche
6.2.4 TVI-Kidney-1 – TVAX Biomedical
6.2.5 Keytruda (pembrolizumab/MK3475) – Merck & Co
6.2.6 Atezolizumab (MPDL3280A) – Roche
6.2.7 Avelumab (MSB0010718C) – Merck
6.3 Monoclonal Antibody Therapies in Development for the Treatment of Renal Cancer
6.3.1 TRC105 – Tracon Pharma
6.3.2 RENCAREX (girentuximab) – WILEX AG
6.3.3 Varlilumab (CDX-1127/ Anti-CD27) – Celldex Therapeutics
6.3.4 ASONEP (sonepcizumab/LT1009) – Lpath Inc
6.4 Novel Anti-Cancer Therapies in the Pipeline for Renal Cancer
6.4.1 CRLX101 – Cerulean Pharma
6.4.2 Entinostat (SNDX-275/MS-275) – Syndax Pharmaceuticals

7. Qualitative Analysis of the Renal Cancer Treatments Market, 2015-2025
7.1 SWOT Analysis of the Renal Cancer Treatment Market
7.1.1 Strengths and Weaknesses of the Market
7.1.2 The Increasing Prevalence of Renal Cancer
7.1.3 A Rise in Ageing Population
7.1.4 Increasing Risk Factors: Obesity and Smoking
7.1.5 The High Cost of Drug Treatments Will Limit Market Growth
7.1.6 Important Patent Expiries Are Looming
7.2 Opportunities and Threats
7.2.1 Novel Therapies: The Rise of Immunotherapy
7.2.2 Combination Therapies: An Opportunity to Improve on Existing Treatments
7.2.3 Regulations: A Hindrance for Growth of the Market

8. Research Interviews
8.1 Interview with Dr Paul Bevan, Head of R&D, WILEX, Munich, Germany
8.1.1 RENCAREX: Possible First Adjuvant Treatment of RCC
8.2 Interview with Gary Wood, PhD, Chief Science Officer, TVAX Biomedical, Kansas, USA
8.2.1 Novel Immunotherapy Treatment for Renal Cancer
8.2.2 The Challenges of Using New Therapies

9. Conclusions
9.1 The Renal Cancer Treatment Market: World Outlook from 2015
9.2 Growth Will Be Driven by an Increase in Demand
9.3 The Global Renal Cancer Treatment Market Will Continue to be Dominated by the US and the EU
9.4 Leading Renal Cancer Treatment Drug Companies
9.5 The Future of the Renal Cancer Treatment Market


【レポート販売概要】

■ タイトル:腎臓がん治療の世界市場動向及び予測
■ 英文:Renal Cancer Treatment: Industry Analysis, R&D Trends and World Market Forecasts 2015-2025
■ 発行日:2015年10月
■ 調査会社:visiongain
■ 商品コード:VGAIN5102609
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。